BIOGEN INC. - COMMON STOCK
134.46
08-July-25 13:45:00
15 minutes delayed
Stocks
+4.33
+3.33%
Today's range
130.32 - 135.58
ISIN
N/A
Source
NASDAQ
-
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
30 Jun 2025 04:30:12 By Nasdaq GlobeNewswire
-
27 Jun 2025 07:00:23 By Nasdaq GlobeNewswire
-
25 Jun 2025 04:30:37 By Nasdaq GlobeNewswire
-
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
18 Jun 2025 04:30:27 By Nasdaq GlobeNewswire
-
11 Jun 2025 22:00:39 By Nasdaq GlobeNewswire
-
27 May 2025 04:30:00 By Nasdaq GlobeNewswire
-
15 Apr 2025 16:00:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
09 Apr 2025 06:45:15 By NetDania Notify
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
08 Apr 2025 10:06:04 By NetDania Notify
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
07 Apr 2025 06:45:03 By NetDania Notify
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
04 Apr 2025 06:47:36 By NetDania Notify
-
02 Apr 2025 04:30:00 By Nasdaq GlobeNewswire
-
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
24 Mar 2025 04:30:00 By Nasdaq GlobeNewswire
-
11 Mar 2025 04:30:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
12 Feb 2025 06:45:10 By NetDania Notify
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
11 Feb 2025 08:11:08 By NetDania Notify
-
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
31 Jan 2025 03:30:52 By Nasdaq GlobeNewswire
-
26 Jan 2025 15:33:52 By Nasdaq GlobeNewswire
-
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
23 Jan 2025 04:30:54 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >